By Connor Hart
Shares of Insmed rose after the company disclosed what it called positive topline results from a study of its treatment for pulmonary arterial hypertension, or high blood pressure in the lungs.
The stock jumped 20%, to $85, in pre-market trading Tuesday. Through Monday's close, shares have gained 18% in the past year.
The biopharmaceutical company said its study evaluating the efficacy and safety of treprostinil palmitil inhalation powder, or TPIP, met its primary endpoint and all secondary efficacy endpoints.
Based on the results of the study, Insmed said it will immediately engage with the Food and Drug Administration about a Phase 3 trial design.
The company plans to start a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease before the end of the year, as well as a Phase 3 trial in patients with pulmonary arterial hypertension in early 2026.
"The statistically significant and clinically meaningful results shown with TPIP in pulmonary arterial hypertension mark a potential breakthrough for patients and the future of prostanoid therapy," Chief Product Strategy Officer Gene Sullivan said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
June 10, 2025 08:38 ET (12:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.